AR and neoplasm: Pharmacological inhibition (with ABC294640) of sphingosine kinase 2 (SphK2), one of the two Sphk isoforms that catalyzes the synthesis of S1P from sphingosine, effectively reduced CRPC cell proliferation and xenograft tumor growth by targeting AR and the oncogene MYC (148).